Jaguar Animal Health Inc (NASDAQ:JAGX) along with Napo Pharmaceuticals, Inc. posted that Dr. Pravin Chaturvedi has been elected as Chair of Scientific Advisory Board, subsequent to the projected completion of the merger of the two firms.
Dr. Chaturvedi has been chairing Napo Scientific Advisory Board since last couple of months. He is accountable for offering supervision on tactics, oversight and plans related to the commercialization and development of the drug pipelines, constituting, but not restricted to, SB-300 and Mytesi®.
From 2006 to 2013, Dr. Chaturvedi was CSO of the Napo and since then has remained a scientific adviser for the company. His notable record of accomplishments constitutes participating in, and directing development plans for 7 drugs, counting Mytesi®, which is authorized by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in subjects with HIV/AIDS and on antiretroviral therapy.
For this specific indication, Dr. Chaturvedi supervised the key opinion leader plans that led to the application of adaptive clinical study format for the Mytesi® study and its nod by the U.S. FDA. As confirmed earlier, Jaguar and Napo had successfully finalized a definitive merger contract.
The two firms are in the course of assessing follow-on indications for Mytesi® under the predicted combination of the product pipelines. Dr. Chaturvedi is chairing Mytesi® study for likely follow-on indications, which constitute irritable bowel syndrome, chemotherapy-related diarrhea, for which POC statistics are already present.
Napo recently planned a Scientific Advisory Board expo with professional gastroenterologists, who presented views on trial subjects and format in IBD and IBS. Douglas Drossman, MD mentioned that the safety profile of crofelemer constitutes a benefit that separates it from other gastrointestinal offerings.
In the last trading session, the stock price of Jaguar declined more than 4% to close the day at $0.660. After the recent decline, the market cap of firms stands around $9.27 million.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: